Fig. 8: Complete EGS Workflow.

a Entry point for platform is to choose a gene and then screen chemical or biological agents using HTS-compatible assays that read-out endogenous protein expression of the gene of interest within disease-modeling state. The test agents could increase protein expression in a variety of ways, with the expected outcome of boosting protein resulting in a switch from “disease” to “healthy” cellular state. b (a, left box) Molecules suitable for further study enter the development pipeline workflows. A compound travels through two distinct sub-paths: (b, top right box) the probe undergoes pre-clinical development toward eventual IND application; (c, bottom right box) probe enters phenotype-to-mechanism studies aimed at identifying its molecular targets and how it regulates signaling to switch the state from “disease” and toward “health”. Created in BioRender. Samowitz, P. (2025) https://BioRender.com/cnld7d3.